Study summary · research use only
Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This randomized controlled trial in 40 human subjects with mild to moderate acne vulgaris compared oral glutathione (500 mg daily, n = 22) with placebo (n = 18) for 4 weeks, measuring serum nitric oxide (NO) and IL-1α and clinical severity via Lehmann criteria. At week 4, the glutathione group showed reductions in serum NO and IL-1α that did not reach statistical significance (p > 0.05). Seven subjects (31.8%) in the glutathione group had clinical improvement, moving from moderate to mild severity. No adverse reactions were reported. The authors describe a non-significant trend toward reduced oxidative and nitrosative stress markers and improved acne severity with oral glutathione, and state further studies are needed to validate the findings.
Abstract
Acne vulgaris (AV) is a chronic inflammatory dermatosis predominantly affecting adolescents and young adults. Oxidative and nitrosative stress, marked by elevated nitric oxide (NO) and interleukin (IL)-1α, contributes to AV pathogenesis. Glutathione, a key antioxidant, may attenuate oxidative and nitrosative stress and modulate inflammatory pathways. This study investigates the effectiveness of oral glutathione supplementation on serum NO and IL-1α concentrations, and clinical improvement in mild to moderate AV patients. A randomized controlled trial was conducted involving 40 subjects diagnosed with mild to moderate AV. Participants were randomized to receive either 500 mg oral glutathione (n = 22) or placebo (n = 18) once daily for 4 weeks. Clinical severity of AV was assessed utilizing the Lehmann criteria. Serum levels of NO and IL-1α were measured at baseline and week 4. At week 4, reductions in serum NO and IL-1α concentrations were observed in the glutathione group; however, these changes did not reach statistical significance (p > 0.05). Clinical improvement occurred in seven subjects (31.8%) in the glutathione group, with a reduction from moderate to mild severity. No adverse reactions were reported. Oral glutathione supplementation demonstrated a non-significant trend toward reducing oxidative and nitrosative stress markers and improving mild to moderate AV. Further studies are recommended to validate these findings.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.